Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1424 • ACR Convergence 2023
Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients
Dafna Gladman¹, Xenofon Baraliakos², Michael Starr³, Roberto Ranza⁴, Emmanouil Rampakakis⁵, Natalie shiff⁶, Francois Nantel⁷, Chenglong Han⁸, Andrew James Knowles Ostor⁹ and Philip J. Mease¹⁰, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Division of Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁴Rheumatology Unit, Hospital das Clínicas da Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁵McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁶Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁷Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁸Immunology, Janssen Global Services, LLC, Malvern, PA, ⁹Cabrini Hospital, Monash University & Emeritus Research / Australian National University, Canberra, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Fatigue is commonly reported by PsA patients (pts) and contributes to disease burden. The fully human IL-23p19-subunit inhibitor guselkumab (GUS) induces clinically meaningful and…
Abstract Number: 1440 • ACR Convergence 2023
Removal of Methotrexate in Patients with Active Psoriatic Arthritis with Newly Induced Ustekinumab Treatment Leads to a Delayed Response in DAPSA and DAS28 Within the First 16 Weeks
Michaela Koehm¹, Ann Christina Foldenauer², Tanja Rossmanith², Herbert Kellner³, Uta Kiltz⁴, Arnd Kleyer⁵, Gerd Burmester⁶, David Kofler⁷, Jan Brandt-Juergens⁸, Raoul Bergner⁹ and Frank Behrens¹⁰, ¹University Hospital Frankfurt, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Frankfurt, Germany, ³Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ⁷University of Cologne, Cologne, Germany, ⁸rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁹Municipal Hospital Ludwigshafen, Department of Internal Medicine A, Nephrology and Rheumatology, Ludwigshafen, Germany, ¹⁰Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Methotrexate (MTX) is often used as first-line DMARD therapy in active psoriatic arthritis (PsA). The value of MTX in combination with different bDMARDs is…
Abstract Number: 1778 • ACR Convergence 2023
Role of GITR/GITRL Interaction in Modulating T Helper 9, T Helper 17 and T Regulatory Response in Psoriatic Arthritis
Chiara Rizzo¹, Lidia La Barbera¹, Marianna Lo Pizzo¹, Leila Mohammadnezhad¹, federica Camarda¹, Francesco Dieli¹, Francesco Ciccia² and Giuliana Guggino¹, ¹University of Palermo, Palermo, Italy, ²University of Campania - Luigi Vanvitelli, Naples, Italy
Background/Purpose: The inflammatory process characterizing Psoriatic Arthritis (PsA) is mainly driven by interleukin (IL)-23/IL-17 axis and IL-9 overexpression, in presence of T helper (Th)17 and…
Abstract Number: 2230 • ACR Convergence 2023
Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year
Laura Coates¹, Robert BM Landewé², Iain McInnes³, Philip J. Mease⁴, Christopher T Ritchlin⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Frank Behrens⁸, Dafna Gladman⁹, Laure Gossec¹⁰, Alice B. Gottlieb¹¹, Richard B. Warren¹², Barbara Ink¹³, Rajan Bajracharya¹³, Jason Coarse¹⁴ and Joseph Merola¹⁵, ¹University of Oxford, Oxford, United Kingdom, ²Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ³University of Glasgow, Glasgow, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁵University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷The Jikei University School of Medicine, Department of Dermatology, Tokyo, Japan, ⁸Goethe University, Division of Rheumatology, University Hospital and Fraunhofer Institute for Translational Medicine & Pharmacology, Frankfurt, Germany, ⁹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ¹⁰Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ¹¹Icahn School of Medicine at Mount Sinai, New York, NY, ¹²Dermatology Centre, Northern Care Alliance NHS Foundation Trust; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ¹³UCB Pharma, Slough, United Kingdom, ¹⁴UCB Pharma, Morrisville, NC, ¹⁵Harvard Medical School, Brigham and Women's Hospital, Newton, MA
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has shown superior efficacy to 16 weeks (wks) vs placebo…
Abstract Number: 2246 • ACR Convergence 2023
Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan
Lars Erik¹, Ahmed Soliman², Dominic Nunag³, Ralph Lippe⁴, Matthew Davis³ and Mitsumasa Kishimoto⁵, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²AbbVie, Inc., North Chicago, IL, ³Medicus Economics, LLC, Milton, MA, ⁴AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁵Kyorin University School of Medicine, Yokohoma, Japan
Background/Purpose: The national prevalence of PsA among patients (pts) with psoriasis (PsO) in Japan is estimated to be 14.3%. Risankizumab (RZB) was approved for the…
Abstract Number: PP04 • ACR Convergence 2023
Bouncing Back: How I Found My Running Shoes Using a Rebounder for My Psoriatic Arthritis
Ashley Krivohlavek, University of Oklahoma, Claremore, OK
Background/Purpose: When I was diagnosed with psoriatic arthritis (PsA) nine years ago, I thought my running days were behind me. Since high school, I have…
Abstract Number: 0054 • ACR Convergence 2023
RA Monocytes and Monocyte-Derived Macrophages Display Heightened Inflammatory Responses, Reduced Endocytic Capacity and Distinct TET Expression Compared to PsA Monocytes
Success Amaechi¹, Megan Hanlon², Alyssa Gilmore², Dumitru Anton², Mary Canavan³, Sonia Sundanum⁴, Carl Orr⁵, Douglas Veale⁶, Viviana Marzaioli⁷ and Ursula Fearon⁸, ¹Trinity College Dublin, Mullingar, Ireland, ²Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ³Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, ⁴EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, ⁵Saint Vincent's University Hospital, Dublin, Ireland, ⁶St.Vincent's University Hosp, Dublin, Ireland, ⁷Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland
Background/Purpose: RA and PsA share various pathogenic features, while also displaying significant differences at the clinical, cellular and molecular levels. In this study, we investigate…
Abstract Number: 0486 • ACR Convergence 2023
Identifying Serum Metabolomic Markers Associated with Psoriasis Skin Disease Activity
Hani Choksi¹, Sheng Han Li², Nikita Looby², Max Kotlyar³, Vathany Kulasingam⁴, Igor Jurisica⁵ and Vinod Chandran⁶, ¹Schroeder Arthritis Institute, Krembil Research Institute, Krembil Research Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriasis is a chronic, immune-mediated inflammatory skin disease that affects over 2.5% of the global population. Approximately 25% of psoriasis patients also have a…
Abstract Number: 0502 • ACR Convergence 2023
Developing Electronic Health Record Algorithms to Accurately Identify Psoriatic Arthritis Patients
Paras Karmacharya¹, Avery Fortier¹, Georgina Sellyn¹, Alexis R Ogdie² and Leslie Crofford³, ¹Vanderbilt University, Nashville, TN, ²University of Pennsylvania, Philadelphia, PA, ³Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, progressive inflammatory disease of the skin and musculoskeletal system, affecting over half a million US adults. With relatively…
Abstract Number: 0777 • ACR Convergence 2023
Characteristics of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis
Cecile PHILIPPOTEAUX¹, Anne Marty-Ane¹, Emeline Cailliau¹, Peggy Philippe¹, Bernard Cortet¹, Julien Paccou¹, Rene-Marc Flipo¹ and Jean-Guillaume Letarouilly², ¹University Hospital Center of Lille, Lille, France, ²CHU Lille, Lille, France
Background/Purpose: The EULAR task force recently published the difficult-to-treat RA (D2T RA) definition [1], however, a definition of D2T PsA is still lacking. To date,…
Abstract Number: 1387 • ACR Convergence 2023
Power Doppler Musculoskeletal Abnormalities in Patients with Psoriasis at High Risk of Progression to Psoriatic Arthritis
Rebecca Haberman¹, Sarah Moussavi¹, Yan Zhang¹, Sydney Catron¹, Jonathan Samuels², Rebecca Blank³, Michael Toprover⁴, Jiyuan Hu¹, Cinty Gong⁵, Vincent Piguet⁶, Francisco Tausk⁷, Jensen Yeung⁸, Andrea Neimann¹, Wayne Gulliver⁹, Joseph Merola¹⁰, Alexis R Ogdie¹¹, Proton Rahman¹², Soumya Chakravarty¹³, Ralf Thiele¹⁴, Lihi Eder¹⁵, Christopher T Ritchlin¹⁶ and Jose Scher¹⁷, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone, Rye Brook, NY, ³New York University, New York, NY, ⁴New York University Langone Health, New York, NY, ⁵Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, USA, Raritan, NJ, ⁶Women's College Hospital, Toronto, ON, Canada, ⁷University of Rochester Medical Center, Rochester, NY, ⁸University of Toronto and Women’s College Hospital, Toronto, ON, Canada, ⁹Memorial University of Newfoundland, St. John's, NL, Canada, ¹⁰Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ¹³Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ¹⁴University of Rochester, Pittsford, NY, ¹⁵Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁶University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY, ¹⁷New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated disease associated with skin psoriasis that, if untreated, can lead to joint destruction. Up to 30% of patients…
Abstract Number: 1425 • ACR Convergence 2023
Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis
Dafna Gladman¹, Peter Nash², Philip J. Mease³, Oliver FitzGerald⁴, Karim R. Masri⁵, Stephanie Duench⁶ and Mary Jane Cadatal⁷, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²School of Medicine, Griffith University, Brisbane, Australia, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁴Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁵Pfizer Inc., Collegeville, PA, ⁶Pfizer Inc., New York, NY, ⁷Pfizer Inc., Manila, Philippines
Background/Purpose: Patients (pts) with PsA and an inadequate response (IR) to conventional synthetic DMARDs are routinely treated with TNF inhibitors (TNFi).1,2 Intolerance/IR to TNFi may…
Abstract Number: 1639 • ACR Convergence 2023
PsA Patients of Diverse Ethnic and Racial Backgrounds Experience More Skin Psoriasis, Increased Pain, and Higher Rates of Radiographic Axial Disease
Rebecca Haberman¹, Tasneem Ahmed², Seungha Um¹, Ying Yin Zhou¹, Sydney Catron¹, Kathryn Jano¹, Sarah Moussavi¹, Eileen Lydon², Alexandra Rice¹, Andrea Neimann¹, Soumya Reddy³, Samrachana Adhikari¹ and Jose Scher⁴, ¹NYU Grossman School of Medicine, New York, NY, ²New York University, New York, NY, ³NYU School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY
Background/Purpose: Individuals of diverse ethnic and racial backgrounds are generally underrepresented in psoriatic arthritis (PsA) research and clinical trials, despite evidence that their disease presentation,…
Abstract Number: 1784 • ACR Convergence 2023
Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model
Raminderjit Kaur¹, M. Elaine Husni², Unnikrishnan Chandrasekharan³ and Roberta Brambilla⁴, ¹Cleveland Clinic, Cleveland,, OH, ²Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH, ⁴University of Miami Miller School of Medicine, Miami,, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, progressive autoimmune condition that affects both the skin and joints. It is characterized by increased levels of the…
Abstract Number: 2231 • ACR Convergence 2023
Ixekizumab Significantly Improves Nail Disease and Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis
Dennis McGonagle¹, Arthur Kavanaugh², Iain McInnes³, Lars Erik⁴, Joseph Merola⁵, Bruce Strober⁶, Rebecca Bolce⁷, Jeffrey Lisse⁷, Jennifer Pustizzi⁷, Christophe Sapin⁷ and Christopher T Ritchlin⁸, ¹Leeds Teaching Hospitals NHS Trust, Academic Unit for the Musculoskeletal Diseases, Leeds, United Kingdom, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ⁶Yale University, New Haven, CT, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY
Background/Purpose: Nail psoriasis (PsO) is a strong predictor for the development of psoriatic arthritis (PsA) and has been reported in 63–83% of patients with PsA1.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].